Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

PURPOSE: We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by genotype-guided tamoxifen dosing in patients with intermediate CYP2D6 metabolism. PATIENTS AND METHODS: O...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Irvin, William J., Walko, Christine M., Weck, Karen E., Ibrahim, Joseph G., Chiu, Wing K., Dees, E. Claire, Moore, Susan G., Olajide, Oludamilola A., Graham, Mark L., Canale, Sean T., Raab, Rachel E., Corso, Steven W., Peppercorn, Jeffrey M., Anderson, Steven M., Friedman, Kenneth J., Ogburn, Evan T., Desta, Zeruesenay, Flockhart, David A., McLeod, Howard L., Evans, James P., Carey, Lisa A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2011
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3158597/
https://ncbi.nlm.nih.gov/pubmed/21768473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.4427
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge